Literature DB >> 27197526

Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?

Marut Yanaranop1, Vahcharapot Anakrat, Somchai Siricharoenthai, Saranyu Nakrangsee, Bandit Thinkhamrop.   

Abstract

AIM: The study aimed to compare the risk of ovarian malignancy algorithm (ROMA) with risk of malignancy index (RMI), cancer antigen 125 (CA125), human epididymis protein 4 (HE4) and Sassone ultrasonography (US) score in predicting ovarian cancer (OC) in women who present with pelvic or adnexal masses.
METHODS: Pelvic US, serum CA125 and HE4 levels were investigated preoperatively in consecutively enrolled Thai women over 18 years with clinically diagnosed pelvic or adnexal masses who were undergoing elective surgery at a super tertiary hospital in Thailand in 2012. ROMA, RMI and Sassone US score were calculated.
RESULTS: Of 260 women who were evaluated, 74 had OC. Areas under the receiver operating characteristic curve (AUC) in predicting OC were ROMA, 86.2%; RMI, 87.6%; CA125, 80.6%; HE4, 82.4%; and Sassone score, 77.1%. ROMA and RMI performed similarly well (AUCs 84.4 and 85.6%) in premenopausal women but RMI outperformed ROMA in postmenopausal women (AUCs 87.9 and 84.0%, respectively). At the conventional cutoff value, ROMA and CA125 showed the highest sensitivity (83.8%) but HE4 had the highest specificity (86.0%).
CONCLUSIONS: ROMA was comparable to RMI in predicting OC. Either ROMA or RMI can be applied to women with pelvic masses, stratified into low- and high-risk groups for OCs.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197526     DOI: 10.1159/000446238

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  9 in total

Review 1.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

2.  The Association between Human Epididymis Secretory Protein 4 and Metabolic Syndrome.

Authors:  Peng-Fei Li; Yu-Jen Lin; Yao-Jen Liang; Wei-Liang Chen
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

3.  Diagnostic performance of biomarkers for ovarian cancer: Protocol for an overview, evidence mapping, and adjusted indirect comparisons.

Authors:  Jinyong Hua; Jing Liu; Mengge Hua; Runjin Cai; Muyang Li; Jing Wang; Jiancheng Wang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial.

Authors:  Vincent Dochez; Mélanie Randet; Céline Renaudeau; Jérôme Dimet; Aurélie Le Thuaut; Norbert Winer; Thibault Thubert; Edouard Vaucel; Hélène Caillon; Guillaume Ducarme
Journal:  J Clin Med       Date:  2019-10-25       Impact factor: 4.241

5.  A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.

Authors:  Pia Leandersson; Anna Åkesson; Ingrid Hedenfalk; Susanne Malander; Christer Borgfeldt
Journal:  PLoS One       Date:  2020-10-19       Impact factor: 3.240

Review 6.  High-throughput approaches for precision medicine in high-grade serous ovarian cancer.

Authors:  Meinusha Govindarajan; Christoph Wohlmuth; Matthew Waas; Marcus Q Bernardini; Thomas Kislinger
Journal:  J Hematol Oncol       Date:  2020-10-09       Impact factor: 17.388

7.  Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study.

Authors:  Francesco Plotti; Corrado Terranova; Federica Guzzo; Carlo De Cicco Nardone; Daniela Luvero; Martina Bartolone; Camilla Dionisi; Domenico Benvenuto; Silvia Fabris; Massimo Ciccozzi; Violante Di Donato; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Biomedicines       Date:  2021-01-08

8.  A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?

Authors:  Miriam Dellino; Giulio Gargano; Raffele Tinelli; Carmine Carriero; Carla Minoia; Skrypets Tetania; Erica Silvestris; Vera Loizzi; Angelo Paradiso; Porzia Casamassima; Antonio Tufaro; Gennaro Cormio; Vito Michele Garrisi
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 9.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.